Senti Biosciences Holdings, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $22,000 | $0 | $2.6M | $4.3M | $2.8M |
| Operating income | -$68.8M | -$61.0M | -$92.7M | -$62.1M | -$40.4M |
| Operating expenses | $68.8M | $61.0M | $95.3M | $66.4M | $43.2M |
| Cash from operations | -$43.4M | -$41.4M | -$52.4M | -$34.9M | -$34.6M |
| Capital expenditure | $196,000 | $26,000 | $12.0M | $41.4M | $5.5M |
| Free cash flow | -$43.6M | -$41.4M | -$64.4M | -$76.3M | -$40.2M |
| Impairments | $5.1M | $313,000 | $26.0M | $0 | $22,000 |
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M | $96.7M |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M | $36.3M |
Shares outstanding 31.1M · Free float 55.6%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.